Effect of Dapagliflozin on VT in Patients With Heart Failure.

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT05550441
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    The experimental group received dapagliflozin (10 mg qd) for 1 year.
  • Placebo — DRUG
    The Placebo group received placebo for 1 year.

Study Details

This project plans to design a randomized controlled clinical trial to evaluate the effect of dapagliflozin on ventricular arrhythmia in the participants with heart failure with reduced ejection fraction after ICD implantation by collecting and analyzing the data of ECG, cardiac ultrasound and ICD programming. This project will explore the anti-ventricular arrhythmia effect of dapagliflozin in HFrEF patients.

Key Dates

Start date
Nov 15, 2022
Status verified
Sep 2022
Primary completion
Nov 15, 2024
Completion
Nov 15, 2024

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo group
  • Experimental: Dapagliflozin group

Primary Outcome Measure

Number of ICD discharges and mode of electrical therapy (ATP, synchronized cardioversion, electrical defibrillation) [ Time Frame: 1 year ]

Central Contacts

Related Studies